Ovid Therapeutics Inc. (1OT.F)
| Previous close | 2.9000 |
| Open | 2.7600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.7600 - 2.7600 |
| 52-week range | 2.4600 - 3.6800 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 204.332M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.75 |
ZacksOvid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Ovid Therapeutics (OVID) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
GlobeNewswireOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in a virtual presentation at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 9:30 a.m. ET. A live webcast of the Needham presentation can be accessed through the Events & Presentations section of
